archTIS Limited (ASX: AR9) operates in a specialised segment of the cybersecurity market focused on data-centric security for government, defence, and regulated industries. The Company’s positioning within Zero Trust architecture and attribute-based access control (ABAC) environments places it in a sector where procurement cycles are long and compliance standards are strict.

Samso has had a late entry to looking at looking at G11 Resources Limited (ASX: G11) as it explores for copper and gold within Tasmania’s Mt Read Volcanic Belt, a region that hosts the Mt Lyell Copper-Gold Mine and several other base metal and gold deposits. The Company’s focus is on structurally controlled mineralisation along the Great Lyell Fault, which is the main structural control to the Mt Lyell ore system.

Samso has had a late entry to looking at looking at G11 Resources Limited (ASX: G11) as it explores for copper and gold within Tasmania’s Mt Read Volcanic Belt, a region that hosts the Mt Lyell Copper-Gold Mine and several other base metal and gold deposits. The Company’s focus is on structurally controlled mineralisation along the Great Lyell Fault, which is the main structural control to the Mt Lyell ore system.

As the followers of Samso know, I am a big fan of Tungsten and the current price of tungsten is just ballistic. I cannot ignore any new news as the current state of the market, assuming it is sustained, changes the economic scenario of projects dramatically. What companies like Viking Mines Ltd (ASX: VKA) is now proposing can no longer be taken in the same light as it would have been when the tungsten pricing was in the USD $400s per mtu. This is the reason investors must

I have been a keen follower of the Kaiser Reef Limited (ASX: KAU) story which was literally an overnight transition to become a profitable Australian gold producer operating in Tasmania and Victoria. The Company owns and operates the Henty Gold Mine in Tasmania and the Maldon Gold Project in Victoria, including the Union Hill Gold Mine and the Porcupine Flat Processing Plant.

I am a shareholder of E79 Gold and I am liking the new potential of the new consolidated 65km² landholding in the Day Dawn goldfield, immediately south of Westgold’s Great Fingall Gold Mine (1.2Moz @ 19.2g/t Au). IN this update, we discuss the completion and the identifying of numerous geophysical targets.

The business of metal health is banking on this growing concern in the general population. The statistics for the general population in regards to some form of depression are staggering and I would bet that there would be easily be only one of two separation before you know someone needing help.

As the copper price continue to rise and global narrative are that the demand for copper is going to create a shock reaction to the market. The time lag that is required to find and then establish the supply infrastructure will struggle to meet the demand for copper.

The month of February has been an interesting release of business pathway for Critical Resources. The company is looking for gold in New Zealand, exploring for lithium in Canada and now looking at transitioning into participating in downstream battery technology validation. The acceptance into CEPS provides an execution pathway for evaluating optioned solid-state lithium-ion battery IP.

Samso is drawn to Legacy Minerals because the Company combines an established, sizeable silver-equivalent resource base with genuine discovery-driven upside at depth and along strike. The commencement of drilling at Mascotte highlights a disciplined strategy focused on unlocking value from historical high-grade systems that have seen minimal modern exploration, particularly for gold.

Control Bionics Limited (ASX: CBL) has announced a new agreement with Tobii Dynavox, a global leader in Augmentative and Alternative Communication (AAC), to evaluate a potential U.S. distribution partnership for its NeuroNode® technology. The agreement initiates a six-month pilot program across five north-western U.S. states, positioning NeuroNode alongside Tobii Dynavox’s established communication aids.

Actinogen Medical Limited (ASX: ACW) is progressing its lead drug candidate, Xanamem (emestedastat), through the XanaMIA Phase 2b/3 Alzheimer’s disease clinical trial being conducted across Australia and the United States. The Company is developing Xanamem as a once-daily oral therapy targeting cortisol regulation in the brain, to slow disease progression in patients with mild to moderate Alzheimer’s disease.